Metabolic syndrome and major depression

Area of Science:

• Neuroscience
• Cardiology
• Endocrinology

Background:

• Major depression is linked to a four-fold increased risk of premature death, predominantly from cardiovascular disease (CVD).
• Metabolic syndrome (MeS), characterized by visceral obesity, dyslipidemia, insulin resistance, and hypertension, frequently co-occurs with depression.
• The shared mechanisms between MeS and depression are not fully understood but may involve common alterations in stress systems and chronic inflammation.

Purpose of the Study:

• To explore the intricate relationship between major depression and metabolic syndrome (MeS).
• To review potential shared pathophysiological pathways linking depression and MeS, including stress system alterations and inflammation.
• To highlight the clinical implications of assessing metabolic risk in depressed patients and suggest novel therapeutic targets.

Main Methods:

• Review of epidemiological studies on the co-occurrence of depression and MeS components.
• Examination of hypotheses regarding shared biological mechanisms, including the hypothalamus-pituitary-adrenal (HPA) axis, immune system, and oxidative stress.
• Consideration of the role of peripheral hormones (leptin, ghrelin) in mood regulation.

Main Results:

• Consistent epidemiological evidence shows a strong association between depression and MeS components.
• Both depression and MeS are associated with a low-grade chronic inflammatory state and increased oxidative and nitrosative (O&NS) damage.
• Peripheral hormones involved in energy balance may also influence mood regulation.

Conclusions:

• Metabolic risk factors should be routinely assessed in patients with major depression.
• Therapeutic strategies for depression may benefit from considering metabolic health.
• Novel antidepressant therapies could target inflammatory pathways, stress systems, and peripheral mediators.